Clinical Trial Update: Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating agatolimod sodium in combination with rituximab and Yttrium-90 ibritumomab tiuxetan for adults with recurrent or refractor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Splenic Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Agatolimod Sodium (agatolimod sodium)
• Rituximab (rituximab)
• Yttrium-90 ibritumomab tiuxetan (yttrium-90 ibritumomab tiuxetan)

Snippet

Sponsor: Mayo Clinic | Conditions: Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-09-01